临床前浸润性上皮性卵巢癌的症状——英国卵巢癌筛查协作试验(UKCTOCS)内嵌的探索性分析
UKCTOCS纳入202638名50至74岁绝经后女性,随机分为不筛查、多模式筛查和超声筛查三组,比较临床前(筛查检出)与临床诊断的浸润性上皮性卵巢癌的症状。共1133例(286例筛查检出,847例临床诊断)发生浸润性上皮性卵巢癌,筛查检出组诊断时中位年龄更早(66.8岁 vs 68.7岁,p=0.0001),两组报告症状的比例分别为48%(112/234)和90%(660/730)。在早期高级别浆液性癌中,筛查检出组更常报告胃肠道症状(35% vs 9%,p=0.001)和全身症状(27% vs 9%,p=0.017)。
要点
- 筛查检出组诊断时中位年龄66.8岁,临床诊断组68.7岁(p=0.0001)。
- 筛查检出组48%(112/234)报告症状,临床诊断组90%(660/730)报告症状。
- 早期高级别浆液性癌中,筛查检出组胃肠道症状35%(9/26)vs 临床诊断组9%(7/80),p=0.001。
核心结论
- 研究结果提示应重新考虑早期输卵管卵巢癌的警示症状,需要在前瞻性试验中评估和优化更细致的核心症状组合。
研究设计与样本
- UKCTOCS内嵌的探索性分析,202638名50至74岁绝经后女性于2001年4月17日至2005年9月29日随机分配(2:1:1)至不筛查或多模式筛查或超声筛查组,筛查持续至2011年12月31日。
- 通过国家登记随访,结局委员会判定卵巢癌诊断、组织类型和分期,纳入截至2014年12月31日初次删失时诊断为浸润性上皮性卵巢癌的女性。
- 症状信息提取自试验临床评估表和医疗记录,采用描述性统计比较筛查检出与临床诊断女性中早期(I/II期)和晚期(III/IV期或无法分期)高级别浆液性癌的症状。
主要发现
- 1133例女性发生浸润性上皮性卵巢癌(286例筛查检出,847例临床诊断),筛查检出组诊断时中位年龄66.8岁 vs 临床诊断组68.7岁(p=0.0001)。
- 筛查检出组48%(112/234)报告症状,临床诊断组90%(660/730)报告症状。
- 有症状的高级别浆液性癌中,筛查检出组50%(13/26)报告超过1个症状,临床诊断组36%(29/80),p=0.213。
- 早期高级别浆液性癌中,筛查检出组胃肠道症状(排便习惯改变和消化不良)35%(9/26)vs 临床诊断组9%(7/80),p=0.001;全身症状(主要为乏力/疲倦)27%(7/26)vs 9%(7/80),p=0.017。
- 晚期高级别浆液性癌中,腹部症状筛查检出组57%(49/86)vs 临床诊断组74%(431/580),p=0.001;早期腹部症状筛查检出组62%(16/26)vs 临床诊断组53%(42/80),p=0.421。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: UKCTOCS provides an opportunity to explore symptoms in preclinical invasive epithelial ovarian cancer (iEOC). We report on symptoms in women with pre-clinical (screen-detected) cancers (PC) compared to clinically diagnosed (CD) cancers. METHODS: In UKCTOCS, 202638 postmenopausal women, aged 50-74 were randomly allocated (April 17, 2001-September 29, 2005) 2:1:1 to no screening or annual screening till Dec 31,2011, using a multimodal or ultrasound strategy. Follow-up was through national registries. An outcomes committee adjudicated on OC diagnosis, histotype, stage. Eligible women were those diagnosed with iEOC at primary censorship (Dec 31, 2014). Symptom details were extracted from trial clinical-assessment forms and medical records. Descriptive statistics were used to compare symptoms in PC versus CD women with early (I/II) and advanced (III/IV/unable to stage) stage high-grade-serous (HGSC) cancer. ISRCTN-22488978; ClinicalTrials.gov-NCT00058032. RESULTS: 1133 (286PC; 847CD) women developed iEOC. Median age (years) at diagnosis was earlier in PC compared to CD (66.8PC, 68.7CD, p = 0.0001) group. In the PC group, 48% (112/234; 90%, 660/730CD) reported symptoms when questioned. Half PC (50%, 13/26PC; 36%, 29/80CD; p = 0.213) women with symptomatic HGSC had >1symptom, with abdominal symptoms most common, both in early (62%, 16/26, PC; 53% 42/80, CD; p = 0.421) and advanced (57%, 49/86, PC; 74%, 431/580, CD; p = 0.001) stages. In symptomatic early-stage HGSC, compared to CD, PC women reported more gastrointestinal (change in bowel habits and dyspepsia) (35%, 9/26PC; 9%, 7/80CD; p = 0.001) and systemic (mostly lethargy/tiredness) (27%, 7/26PC; 9%, 7/80CD; p = 0.017) symptoms. CONCLUSIONS: Our findings, add to the growing evidence, that we should reconsider what constitutes alert symptoms for early tubo-ovarian cancer. We need a more nuanced complex of key symptoms which is then evaluated and refined in a prospective trial.
引用
- Dilley J, Gentry-Maharaj A, Ryan A, et al. Ovarian cancer symptoms in pre-clinical invasive epithelial ovarian cancer - An exploratory analysis nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Gynecol Oncol. 2023. PMID: 37980767. doi:10.1016/j.ygyno.2023.11.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。